Alkem Laboratories Limited
Alkem Laboratories Limited, a pharmaceutical company, engages in the research and development, manufacture, and sale of pharmaceutical and nutraceutical products in India, the United States, and internationally. The company offers branded generics, generic drugs, active pharmaceutical ingredients, and biosimilars, and nutraceuticals in acute and chronic therapeutic areas comprising anti-infective… Read more
Alkem Laboratories Limited (ALKEM) - Net Assets
Latest net assets as of September 2025: ₹138.11 Billion INR
Based on the latest financial reports, Alkem Laboratories Limited (ALKEM) has net assets worth ₹138.11 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹202.87 Billion) and total liabilities (₹64.77 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹138.11 Billion |
| % of Total Assets | 68.08% |
| Annual Growth Rate | 16.83% |
| 5-Year Change | 64.51% |
| 10-Year Change | 228.33% |
| Growth Volatility | 13.93 |
Alkem Laboratories Limited - Net Assets Trend (2010–2025)
This chart illustrates how Alkem Laboratories Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Alkem Laboratories Limited (2010–2025)
The table below shows the annual net assets of Alkem Laboratories Limited from 2010 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹124.34 Billion | +16.05% |
| 2024-03-31 | ₹107.14 Billion | +13.56% |
| 2023-03-31 | ₹94.35 Billion | +6.64% |
| 2022-03-31 | ₹88.47 Billion | +17.06% |
| 2021-03-31 | ₹75.58 Billion | +19.80% |
| 2020-03-31 | ₹63.09 Billion | +13.23% |
| 2019-03-31 | ₹55.72 Billion | +11.77% |
| 2018-03-31 | ₹49.85 Billion | +8.78% |
| 2017-03-31 | ₹45.83 Billion | +21.02% |
| 2016-03-31 | ₹37.87 Billion | +22.77% |
| 2015-03-31 | ₹30.85 Billion | +16.18% |
| 2014-03-31 | ₹26.55 Billion | +11.85% |
| 2013-03-31 | ₹23.74 Billion | +24.58% |
| 2012-03-31 | ₹19.06 Billion | +63.22% |
| 2011-03-31 | ₹11.67 Billion | -3.14% |
| 2010-03-31 | ₹12.05 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Alkem Laboratories Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 10641.3% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹99.73 Billion | 83.21% |
| Common Stock | ₹239.10 Million | 0.20% |
| Other Comprehensive Income | ₹19.88 Billion | 16.59% |
| Total Equity | ₹119.85 Billion | 100.00% |
Alkem Laboratories Limited Competitors by Market Cap
The table below lists competitors of Alkem Laboratories Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Independent Bank Group Inc
NASDAQ:IBTX
|
$2.42 Billion |
|
Vietnam National Petroleum Group
VN:PLX
|
$2.42 Billion |
|
Dhc Software Co Ltd
SHE:002065
|
$2.42 Billion |
|
Loar Holdings Inc.
NYSE:LOAR
|
$2.42 Billion |
|
Anhui Gujing Distillery Co Ltd
SHE:200596
|
$2.42 Billion |
|
Telix Pharmaceuticals Limited
PINK:TLPPF
|
$2.42 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
$2.42 Billion |
|
TBC Bank Group PLC
PINK:TBCCF
|
$2.42 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Alkem Laboratories Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 103,120,600,000 to 119,848,700,000, a change of 16,728,100,000 (16.2%).
- Net income of 21,654,800,000 contributed positively to equity growth.
- Dividend payments of 5,046,200,000 reduced retained earnings.
- Other comprehensive income increased equity by 95,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹21.65 Billion | +18.07% |
| Dividends Paid | ₹5.05 Billion | -4.21% |
| Other Comprehensive Income | ₹95.00 Million | +0.08% |
| Other Changes | ₹24.50 Million | +0.02% |
| Total Change | ₹- | 16.22% |
Book Value vs Market Value Analysis
This analysis compares Alkem Laboratories Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.34x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 53.09x to 5.34x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2010-03-31 | ₹100.80 | ₹5351.50 | x |
| 2011-03-31 | ₹119.39 | ₹5351.50 | x |
| 2012-03-31 | ₹159.37 | ₹5351.50 | x |
| 2013-03-31 | ₹198.54 | ₹5351.50 | x |
| 2014-03-31 | ₹222.06 | ₹5351.50 | x |
| 2015-03-31 | ₹250.83 | ₹5351.50 | x |
| 2016-03-31 | ₹308.78 | ₹5351.50 | x |
| 2017-03-31 | ₹373.66 | ₹5351.50 | x |
| 2018-03-31 | ₹406.79 | ₹5351.50 | x |
| 2019-03-31 | ₹454.93 | ₹5351.50 | x |
| 2020-03-31 | ₹515.26 | ₹5351.50 | x |
| 2021-03-31 | ₹616.96 | ₹5351.50 | x |
| 2022-03-31 | ₹722.44 | ₹5351.50 | x |
| 2023-03-31 | ₹756.52 | ₹5351.50 | x |
| 2024-03-31 | ₹862.46 | ₹5351.50 | x |
| 2025-03-31 | ₹1002.36 | ₹5351.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Alkem Laboratories Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 18.07%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 16.70%
- • Asset Turnover: 0.73x
- • Equity Multiplier: 1.48x
- Recent ROE (18.07%) is above the historical average (17.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2010 | 19.50% | 17.49% | 0.86x | 1.29x | ₹1.15 Billion |
| 2011 | 22.66% | 19.57% | 0.64x | 1.81x | ₹1.81 Billion |
| 2012 | 22.33% | 21.78% | 0.61x | 1.67x | ₹2.35 Billion |
| 2013 | 20.90% | 21.40% | 0.57x | 1.71x | ₹2.59 Billion |
| 2014 | 16.53% | 14.27% | 0.71x | 1.64x | ₹1.73 Billion |
| 2015 | 13.06% | 10.55% | 0.70x | 1.77x | ₹916.85 Million |
| 2016 | 20.09% | 15.24% | 0.88x | 1.50x | ₹3.72 Billion |
| 2017 | 19.97% | 15.88% | 0.86x | 1.47x | ₹4.45 Billion |
| 2018 | 12.97% | 9.99% | 0.82x | 1.58x | ₹1.45 Billion |
| 2019 | 13.98% | 10.47% | 0.89x | 1.51x | ₹2.17 Billion |
| 2020 | 18.29% | 13.76% | 0.82x | 1.61x | ₹5.11 Billion |
| 2021 | 21.49% | 17.97% | 0.77x | 1.56x | ₹8.47 Billion |
| 2022 | 19.05% | 15.47% | 0.76x | 1.63x | ₹7.82 Billion |
| 2023 | 10.88% | 8.48% | 0.84x | 1.52x | ₹796.41 Million |
| 2024 | 17.41% | 14.29% | 0.81x | 1.51x | ₹7.65 Billion |
| 2025 | 18.07% | 16.70% | 0.73x | 1.48x | ₹9.67 Billion |
Industry Comparison
This section compares Alkem Laboratories Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $11,190,336,025
- Average return on equity (ROE) among peers: 13.97%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Alkem Laboratories Limited (ALKEM) | ₹138.11 Billion | 19.50% | 0.47x | $2.42 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $12.11 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $152.86 Million |
| Abbott India Limited (ABBOTINDIA) | $42.33 Billion | 33.41% | 0.40x | $1.58 Billion |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.48 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $128.49 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.92 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $335.22 Million |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.57 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.61 Million |